ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1047

Cost-Effectiveness of Drug-Level Guided Adalimumab Dosing

Zara Izadi1, Gabriela Schmajuk2, Milena Gianfrancesco3, Laura Trupin4, Kashif Jafri5, Jinoos Yazdany4 and Dhruv Kazi6, 1Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, 2San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, 3Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 4Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, 5University of California, San Francisco, San Francisco, CA, 6Department of Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: adalimumab and economics, Crohn's Disease

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 6, 2017

Session Title: Health Services Research Poster II: Osteoarthritis and Rheumatoid Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Adalimumab (ADA) induces and maintains clinical remission in patients with rheumatoid arthritis (RA) and Crohn’s disease (CD) but is an expensive drug. Drug-level and antidrug antibody testing has the potential to facilitate personalization of dosing, particularly the use of less frequent dosing of ADA (de-escalation). The cost-effectiveness of drug-level guided dose de-escalation of therapy is unknown.

Methods: We evaluated the effectiveness (in quality adjusted life years [QALYs]) and cost-effectiveness of a drug-level guided dose-reduction strategy for ADA compared with standard dosing in patients with CD who are in clinical remission, from a health system perspective using a 4-year horizon. We chose CD rather than RA because drug-level guided dose de-escalation studies have not been conducted in RA. We developed a discrete-time Markov simulation model for the analysis, using inputs from published randomized controlled trials and observational studies. The intervention studied was reduction in frequency of ADA dosing from 40mg every other week (EOW) to 40mg every three weeks (ETW) among patients with sustained clinical remission and therapeutic ADA trough levels. Patients who lost clinical remission would undergo drug-level testing. A switch to an alternate biologic was indicated with positive antidrug antibodies or drug resistance (adequate levels despite active symptoms); otherwise the dose was re-escalated back to 40mg EOW. Standard dosing (control arm) involved continuation of 40mg EOW dosing and switch to an alternate biologic on loss of clinical remission.

Results: Among patients with CD in remission on standard dose ADA, reductions in dose yielded similar QALYs but lower costs compared with continuing standard dosing strategy. The difference between the standard and dose-reduction strategies ranged from 0.00 to 0.06 QALYs across the range of probabilities tested (with standard strategy being marginally more effective), but the intervention resulted in cost-savings in every circumstance. In sensitivity analyses, the dose-reduction strategy was the dominant option (less costly and more effective) when ≥87% of patients who were controlled on standard dosing continued to be in remission under the dose-reduction strategy. The findings were most sensitive to the probability of formation of antidrug antibodies after dose reduction and the cost of ADA.

Conclusion: Based on lower costs and similar overall efficacy, dose reduction may be a cost-saving alternative among patients with CD who are in sustained remission with therapeutic ADA levels. These findings suggest that further research to explore drug-level guided tapering in RA may also be warranted. Given the small difference we observed in incremental effectiveness, our proposed strategy may prove to be dominating if future studies also demonstrate that reduced dosing improves the safety of ADA.


Disclosure: Z. Izadi, None; G. Schmajuk, None; M. Gianfrancesco, None; L. Trupin, None; K. Jafri, None; J. Yazdany, None; D. Kazi, None.

To cite this abstract in AMA style:

Izadi Z, Schmajuk G, Gianfrancesco M, Trupin L, Jafri K, Yazdany J, Kazi D. Cost-Effectiveness of Drug-Level Guided Adalimumab Dosing [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/cost-effectiveness-of-drug-level-guided-adalimumab-dosing/. Accessed January 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cost-effectiveness-of-drug-level-guided-adalimumab-dosing/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.